Explore
Validate
Learn
Western blot
Blocking/NeutralizingAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Blocking/Neutralizing [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- AF2037 - Provider product page
- Provider
- R&D Systems
- Product name
- Human Complement Component C5/C5a Antibody
- Antibody type
- Polyclonal
- Description
- Antigen Affinity-purified. Detects human Complement Component C5/C5a in direct ELISAs and Western blots. In Western blots, approximately 5% cross-reactivity with recombinant mouse Complement Component C5a is observed.
- Reactivity
- Human
- Host
- Goat
- Conjugate
- Unconjugated
- Antigen sequence
P01031- Isotype
- IgG
- Vial size
- 100 ug
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references Sexual dimorphism of liver metastasis by murine pancreatic neuroendocrine tumors is affected by expression of complement C5.
Production of C5a by ASP, a serine protease released from Aeromonas sobria.
Production of C5a by ASP, a serine protease released from Aeromonas sobria.
Contractor T, Kobayashi S, da Silva E, Clausen R, Chan C, Vosburgh E, Tang LH, Levine AJ, Harris CR
Oncotarget 2016 May 24;7(21):30585-96
Oncotarget 2016 May 24;7(21):30585-96
Production of C5a by ASP, a serine protease released from Aeromonas sobria.
Nitta H, Imamura T, Wada Y, Irie A, Kobayashi H, Okamoto K, Baba H
Journal of immunology (Baltimore, Md. : 1950) 2008 Sep 1;181(5):3602-8
Journal of immunology (Baltimore, Md. : 1950) 2008 Sep 1;181(5):3602-8
Production of C5a by ASP, a serine protease released from Aeromonas sobria.
Nitta H, Imamura T, Wada Y, Irie A, Kobayashi H, Okamoto K, Baba H
Journal of immunology (Baltimore, Md. : 1950) 2008 Sep 1;181(5):3602-8
Journal of immunology (Baltimore, Md. : 1950) 2008 Sep 1;181(5):3602-8
No comments: Submit comment
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- Chemotaxis Induced by Complement Component C5a and Neutralization by Human Complement Component C5a Antibody. Recombinant Human Complement Component C5a (Catalog # 2037-C5) chemoattracts the J774A.1 mouse reticulum cell sarcoma macrophage cell line in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Human Complement Component C5a (15 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human Complement Component C5a Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2037). The ND50 is typically 0.075-0.4 µg/mL.
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- N-Acetyl-beta -D-Glucosamini-dase Release Induced by Complement Component C5a and Neutralization by Human Complement Component C5a Antibody. Recombinant Human Complement Component C5a (Catalog # 2037-C5) induces N-acetyl- beta -D-glucosaminidase release in the the dibutyryl cyclic-AMP differentiated U937 human histiocytic lymphoma cell line in a dose-dependent manner (orange line). N-Acetyl-beta -D-Glucosamin-idase Release elicited by Recombinant Human Complement Component C5a (15 ng/mL) is neutralized (green line) by increasing concen-trations of Goat Anti-Human Complement Component C5a Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2037). The ND50 is typically 0.15-0.75 μg/mL in the presence of cytochalasin-B.
